# US 2026/0248788 A1 · New compounds and treatment of renal cell carcinoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0248788 A1
- Document ID: US20260248788A1
- Status: Published application
- Kind: A1
- Application number: 19/159,949
- Filed: 2023-09-06
- Published: 2026-08-27
- Earliest claimed: 2023-03-02
- Assignees: Trustlife Therapeutics Inc.
- Applicants: Trustlife Therapeutics Inc.
- Inventors: Adil MARDINOGLU; Xiangyu LI; Younos BOUZIAN; Mohamed EL HAFI; Negar PARVIZI
- Web page: https://patentgrep.com/patent/US20260248788A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/585: containing lactone rings, e.g. oxandrolone, bufalin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 239/48: Two nitrogen atoms
- C07D 239/49: with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
- C07D 239/94: Nitrogen atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/14: containing three or more hetero rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

There is provided a compound according to formula (I), or a pharmaceutically acceptable salt or prodrug thereof.

## Claims

### Claim 1

A compound according to any of the following formulas
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim at position 2

2-11. (canceled)

### Claim 12 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1.

### Claim 13 (depends on 1)

A method of treating renal cell carcinoma in a patient, comprising administering to the patient TG-101209, M7 or a compound according to claim 1, wherein M7 is a compound according to formula (IV)

### Claim 14 (depends on 13)

The method of claim 13, wherein the renal cell carcinoma is stage I-III ccRCC.

### Claim 15 (depends on 13)

The method of claim 13, wherein the method further comprises administering a drug selected from the group consisting of tyrosine kinase inhibitors (e.g. axitinib, sorafenib, pazopanib and sunitinib), mTOR inhibitors (e.g. everolimus and tesirolimus), monoclonal antibodies against VEGF (e.g. bevacizumab), panobinostat, NVP-TAE684 and withaferin-a.

### Claim 16 (depends on 13)

The method of claim 13, wherein the renal cell carcinoma is clear cell renal cell carcinoma (ccRCC).

### Claim 17 (depends on 14)

The method of claim 14, wherein the renal cell carcinoma is stage I or II ccRCC.
